Black Diamond Therapeutics, Inc. (BDTX) Price Target Trimmed as Piper Updates Biotech Models and 2026 Catalyst Tracker

TheFly reported connected January 16 that Piper Sandler lowered the terms people for BDTX to $8 from $9 and maintained an Overweight rating. The alteration coincided with the company’s revision of respective models and terms estimates passim its biotechnology coverage, arsenic good arsenic an update to its 2026 Catalyst Tracker.

Separately, connected December 3, 2025, Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) released affirmative Phase 2 information for silevertinib successful frontline NSCLC with non-classical EGFR mutations and demonstrated robust CNS enactment with a 60% effect rate. The institution plans to negociate with the FDA and transportation retired a randomized Phase 2 glioblastoma survey successful 2026 with backing done the 2nd fractional of 2028.

Following this, connected December 3, Guggenheim did not acceptable a terms nonsubjective for BDTX and alternatively reduced its proposal from Buy to Neutral. The anticipated 2Q26 progression-free endurance effect and the planned Phase 3 trial’s accrued hazard were highlighted by expert Brad Canino.

Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) is simply a clinical-stage oncology institution that focuses connected processing MasterKey therapies that people families of oncogenic mutations crossed tumors. Its pipeline includes brain-penetrant, precision small-molecule inhibitors successful trials for EGFR and different mutation-driven cancers, which purpose to code unmet needs successful coagulated tumors.

While we admit the imaginable of BDTX arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 12 Best Multibagger Stocks to Buy Heading into 2026 and 7 Best Rising Tech Stocks to Buy Now.

Disclosure: None.